Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423007 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00423007 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 90 participants.
The verdict
NCT00423007, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment in subjects with a history of allergic conjunctivitis
Interventions
- DRUG Placebo
- DRUG Bromfenac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423007
The ClinicalTrials.gov registry entry for NCT00423007 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00423007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423007 about?
NCT00423007 is a clinical study titled "Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis". The primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment in subjects with a history of allergic conjunctivitis
What is the current status of trial NCT00423007?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2006-11. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00423007?
The interventions under investigation include: Placebo (DRUG), Bromfenac (DRUG).
Who is sponsoring clinical trial NCT00423007?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.